All results
11 results for phase 2 clinical trial patients metastatic neuroblastoma bone
-
Clinical Trials
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study…
-
Clinical Trials
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in…
-
Clinical Trials
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA)…
-
Clinical Trials
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
-
Clinical Trials
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…
-
Clinical Trials
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…
-
Clinical Trials
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of…
-
Clinical Trials
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high…
-
News, Stories & Blog
Welcome to 2012, OTSP readers! As we approached the New Year, whether you were taking a well-deserved holiday or continuing to work on your research or serve…
-
DoctorsJohn A Ligon , MD
Pediatric Hematologist/Oncologist (Child Cancer Specialist), Pediatrician (Kids / Children Specialist)
John A Ligon, MD is a pediatric hematologist/oncologist (child cancer specialist) practicing at UF Health Pediatric Blood & Marrow Transplant and Cellular…